Drug
Tanespimycin clinical trials
Also written 17-AAG and IPI-504.
- studies test it
- 51
- open now
- 0
- in phase 3
- 3
- first study started
- 1998
How studies write it
Studies that test it under each name
Name
Development codes
Other names
Combined with it in one product
Studies by the year they started
51 studies that test it; most in 2005 (13)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 1999 | 4 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 11 |
| 2005 | 13 |
| 2006 | 3 |
| 2007 | 5 |
| 2008 | 6 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 29
- Phase 2
- 24
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 32
National Cancer Institute (NCI) (24) · Infinity Pharmaceuticals, Inc. (13) · Bristol-Myers Squibb (4) · Cancer Research UK (2) · Memorial Sloan Kettering Cancer Center (2) · Jonsson Comprehensive Cancer Center (1) · National Institutes of Health Clinical Center (CC) (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Bortezomib (5) · Gemcitabine (3) · Docetaxel (3) · Sorafenib (2) · Everolimus (1) · Cytarabine (1) · Irinotecan (1) · Cisplatin (1)
Studies
Open first, then newest update. How each study uses tanespimycin is read from its arms, and is right about nine times in ten.
Testing it · 51
- IPI-504 in NSCLC Patients With ALK TranslocationsTerminatedPhase 2Massachusetts General HospitalNCT01228435Written as IPI-504
- 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone TherapyCompletedPhase 2National Cancer Institute (NCI)NCT00118092Written as tanespimycin
- Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid CancerCompletedPhase 2National Cancer Institute (NCI)NCT00118248Written as tanespimycin
- Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast CancerTerminatedPhase 2National Cancer Institute (NCI)NCT00096109Written as tanespimycin
- A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple MyelomaCompletedPhase 2/3Bristol-Myers SquibbNCT00514371Written as tanespimycin
- Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedPhase 2National Cancer Institute (NCI)NCT00082966Written as 17-N-allylamino-17-demethoxygeldanamycin/bortezomib
- Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed HerceptinCompletedPhase 1/2Bristol-Myers SquibbNCT00773344Written as Tanespimycin
- Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating TanespimycinCompletedPhase 2Bristol-Myers SquibbNCT00779428Written as Tanespimycin
- Dose Escalation of IPI-493 in Hematologic MalignanciesTerminatedPhase 1Infinity Pharmaceuticals, Inc.NCT01193491Written as IPI-493
- A Phase 1 Dose Escalation Study of IPI-493TerminatedPhase 1Infinity Pharmaceuticals, Inc.NCT00724425Written as IPI-493
- Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated LiposarcomaWithdrawnPhase 2Infinity Pharmaceuticals, Inc.NCT00969917Written as IPI-504
- Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung CancerCompletedPhase 1/2Infinity Pharmaceuticals, Inc.NCT01427946Written as IPI-504
- Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic CancerCompletedPhase 2National Cancer Institute (NCI)NCT00577889Written as tanespimycin
- 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT00121264Written as tanespimycin
- Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT00058253Written as tanespimycin
- 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's LymphomaCompletedPhase 2National Cancer Institute (NCI)NCT00117988Written as tanespimycin
- Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity CancerCompletedPhase 2National Cancer Institute (NCI)NCT00093496Written as tanespimycin
- A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung CancerCompletedPhase 2Infinity Pharmaceuticals, Inc.NCT01362400Written as IPI 504 plus Docetaxel
- Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTerminatedPhase 1National Cancer Institute (NCI)NCT00096005Written as tanespimycin
- Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaTerminatedPhase 1National Cancer Institute (NCI)NCT00019708Written as tanespimycin
Codes
What other systems call tanespimycin · ClinicalTrials.gg INT004080
- MeSH (NLM) C112765tanespimycinOne source NLM
- UNII (FDA) 4GY0AVT3L4TANESPIMYCINConfirmed FDA, NLM, Wikidata
- Wikidata Q4552288tanespimycinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C37899TanespimycinOne source FDA
- DrugBank DB05134One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C112765 | tanespimycin | One source NLM |
| UNII (FDA) | 4GY0AVT3L4 | TANESPIMYCIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4552288 | tanespimycin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C37899 | Tanespimycin | One source FDA |
| DrugBank | DB05134 | — | One source Wikidata |
Also registered as retaspimycin (UNII BZF2ZM0I5Z) and retaspimycin hydrochloride (UNII 928Q33Q049).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.